This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Validation of a Real-time Urodynamic Measure of Urinary Urgency

This study has been completed.
Sponsor:
Collaborator:
Astellas Pharma Inc
Information provided by (Responsible Party):
Loyola University
ClinicalTrials.gov Identifier:
NCT00909428
First received: May 26, 2009
Last updated: April 18, 2017
Last verified: April 2017
Results First Received: August 21, 2009  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: No masking;   Primary Purpose: Treatment
Condition: Overactive Bladder Syndrome
Intervention: Drug: Solifenacin Succinate

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Fifty-one individuals were consented and 42 women with overactive bladder (OAB) received study drug between January 2007 and February 2009. Participants were recruited using physician solicitation.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Following informed consent, nine women were negative for OAB and did not receive solifenacin succinate

Reporting Groups
  Description
Detrusor Overactivity Incontinence (DOI) Patients in this cohort were diagnosed with detrusor overactivity incontinence (DOI).
Urodynamic Stress Incontinence (USI) Patients in this cohort were diagnosed with urodynamic stress incontinence (USI)
Mixed Incontinence (DOI-USI) Patients in this cohort were diagnosed with both detrusor overactivity incontinence (DOI) and urodynamic stress incontinence (USI)

Participant Flow:   Overall Study
    Detrusor Overactivity Incontinence (DOI)   Urodynamic Stress Incontinence (USI)   Mixed Incontinence (DOI-USI)
STARTED   18   15   9 
COMPLETED   5   5   0 
NOT COMPLETED   13   10   9 
Lost to Follow-up                13                10                9 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The baseline analysis population comprises all women who signed informed consent and have a valid diagnosis of OAB

Reporting Groups
  Description
Detrusor Overactivity Incontinence (DOI) Patients in this cohort were diagnosed with detrusor overactivity incontinence (DOI)
Urodynamic Stress Incontinence (USI) Patients in this cohort were diagnosed with urodynamic stress incontinence (USI)
Mixed Incontinence (DOI-USI) Patients in this cohort were diagnosed with both detrusor overactivity incontinence (DOI) and urodynamic stress incontinence (USI)
Total Total of all reporting groups

Baseline Measures
   Detrusor Overactivity Incontinence (DOI)   Urodynamic Stress Incontinence (USI)   Mixed Incontinence (DOI-USI)   Total 
Overall Participants Analyzed 
[Units: Participants]
 18   15   9   42 
Age 
[Units: Participants]
Count of Participants
       
<=18 years      0   0.0%      0   0.0%      0   0.0%      0   0.0% 
Between 18 and 65 years      14  77.8%      11  73.3%      9 100.0%      34  81.0% 
>=65 years      4  22.2%      4  26.7%      0   0.0%      8  19.0% 
Sex: Female, Male 
[Units: Participants]
Count of Participants
       
Female      18 100.0%      15 100.0%      9 100.0%      42 100.0% 
Male      0   0.0%      0   0.0%      0   0.0%      0   0.0% 


  Outcome Measures

1.  Primary:   Change in Maximal Cystometric Capacity (mL)   [ Time Frame: 30 Days ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The trial experienced significant attrition. Otherwise, there are no limitations or caveats to report.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Mary P FitzGerald
Organization: Loyola University Chicago
phone: 708-216-2170
e-mail: mfitzg8@lumc.edu


Publications:

Responsible Party: Loyola University
ClinicalTrials.gov Identifier: NCT00909428     History of Changes
Other Study ID Numbers: 109248
Study First Received: May 26, 2009
Results First Received: August 21, 2009
Last Updated: April 18, 2017